Quick Answer
Oncology Institute, Inc. reported Diluted EPS of $0.54 per share (loss) for fiscal year 2025.
Oncology Institute, Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$0.54 | +23.9% |
| 2024 | -$0.71 | +22.8% |
| 2023 | -$0.92 | -338.1% |
| 2022 | -$0.21 | -31.2% |
| 2021 | -$0.16 | +33.3% |
| 2020 | -$0.24 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$0.14 | +22.2% | +6.7% |
| June 30, 2025 | -$0.15 | +11.8% | +28.6% |
| March 31, 2025 | -$0.21 | +4.5% | -16.7% |
| September 30, 2024 | -$0.18 | +5.3% | -5.9% |
| June 30, 2024 | -$0.17 | +10.5% | +22.7% |
| March 31, 2024 | -$0.22 | +33.3% | -15.8% |
| September 30, 2023 | -$0.19 | -11.8% | +0.0% |
| June 30, 2023 | -$0.19 | -216.7% | +42.4% |
- Oncology Institute, Inc. showed an increase of +23.9% in Diluted EPS compared to the prior fiscal year.
- Over the 2020–2025 period, Oncology Institute, Inc.’s diluted eps has declined by 125.0% (from $0.24 per share (loss) to $0.54 per share (loss)).
- The most recent figure is from Oncology Institute, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 12, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: